Abstract: Abstract of the Disclosure The invention relates to a dosage regimen for emergency contraception, to pharmaceutical compositions of the same purpose, to the use of levenorgestrel for the manufacture of pharmaceutical compositions for the same purpose, as well as to the manufacturing process of these pharmaceutical compositions. According to the invention the emergency contraception carried out by the use of levonorgestrel as active ingredient is characterised by administering a single application dose containing 1.5 ± 0.2 mg of levonorgestrel as active ingredient up to 72 hours after the coitus. The pharmaceutical compositions for emergency contraception according to the invention contain only 1.5 ± 0.2 mg of levonorgestrel as active ingredient in each application dose in admixture with known excipients, diluents, flavoring or aromatizing, stabilizers, as well as formulation-promoting or formulation-providing additives, commonly used in the pharmaceutical practice.

Abstract: The invention relates to a dosage regimen for emergency contraception, to pharmaceutical compositions of the same purpose, to the use of levenorgestrel for the manufacture of pharmaceutical compositions for the same purpose, as well as to the manufacturing process of these pharmaceutical compositions. According to the invention the emergency contraception carried out by the use of levonorgestrel as active ingredient is characterised by administering a single application dose containing 1.5±0.2 mg of levonorgestrel as active ingredient up to 72 hours after the coitus. The pharmaceutical compositions for emergency contraception according to the invention contain only 1.5±0.2 mg of levonorgestrel as active ingredient in each application dose in admixture with known excipients, diluents, flavoring or aromatizing, stabilizers, as well as formulation-promoting or formulation-providing additives, commonly used in the pharmaceutical practice.